seitlicher Menuepunkt
SUCHE
Suchbegriff

SUCHE
 
seitlicher Menuepunkt
LOGIN

Für registrierte User stehen verschiedene Download-Dokumente zu den einzelnen Studien zur Verfügung. Dazu können Sie sich im Login-Bereich links auf dieser Seite einloggen.

Studien-Suche:

Alle Studien


Studien: AGMT_NHL-15B |  HD 21 |  AGMT_MM2 |  Ro-CHOP |  AGMT_SAKK 41/14 ACTIVE-2  |  AGMT_HNO_PN |  AGMT_MBC-10 |  AGMT_ALCL1 |  AGMT_MM-1/ EMN-13 |  AGMT_HIV1 |  AGMT_HNO-2 |  HD 17 |  CLL9 |  AGMT_ERCC1 |  HO95/EMN02 |  AGMT_MALT-2 |  HD 16 |  AGMT-Capecet_PK |  AGMT_Sportstudie |  SAKK 75/08 |  REMARC |  Gastric 4 |  AGMT_CMML 1 |  AGMT_NSCLC 1 |  CLL-8/A Mabtenance |  PTCL 1 |  NHL 7-2008/A |  Gastric 3 |  CLL-6 BendAlem |  MBC 5 |  AGMT_ECa |  HD 18 |  ML20523_MALT |  CLL-5 RevliRit |  NHL-14 |  KRK 0504 |  CLL-4 CHAIROS |  HD 13 |  HD 14 |  HD 15 |  CLL-ic NHL II |  HD 10 |  HD 11 |  CLL-ic |  02/89 |  01/89 |  Protokoll 86 |  Protokoll 87 |  Protokoll 89 |  CaelNav 1st Line |  Flusalem |  Gastric 1 |  Gastric 2 |  GemVin 2nd Line |  HD 12 |  NHL-01 |  NHL-10 |  NHL-11 |  NHL-12 |  NHL-13 |  NHL-02 |  NHL-03 |  NHL-05 |  NHL-04, 06 und 07 |  NHL-08 |  NHL-09 |  HNO Studie: Induktions-CT + Radioimmuntherapie |  MinT Follow-Up |  Vin Mono |  GemVin 1st Line |  CaelMono 2nd Line |  VinInt 2nd Line |  AGMT_CML 1 |  AGMT MBC-6 | 

 


AGMT_NHL-15B

Coordinating Investigator: Univ.-Prof. Dr. Ulrich Jäger
Fallzahl: 21
Start: Q1 2017 | Ende: Q2 2020
Status: recruiting


Phase II single-arm \"window-of-opportunity\" study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Studiendesign

Obinutuzumab will be given i.v. at a dose of 1000 mg on days 1, 8, 15 in cycle 1 and on day 1 of each following cycles. Venetoclax will be given at 800mg daily p.o. One cycle is 21 days.
This combination treatment will be repeated for up to 3 cycles.
Eligible patients will then proceed to stem cell transplantation.
A 9 cycles (27 weeks) maintenance phase with obinutuzumab and venetoclax will be given in patients ineligible for transplant.
The study will have a 6 patient run-in phase to determine safety and to adjust treatment. After 10 patients a futility analysis is planned.
A Data Safety Monitoring Board (DSMB) will review the safety data once the study is opened.

The first response assessment (including PET-CT) will be performed after the first cycle of obinutuzumab + venetoclax and patients with at least stable disease (SD) or better will be given another 2 cycles of therapy and then have assessment after a total of 3 cycles. Patients with complete or partial remission (CR, PR) after 3 cycles of therapy will either go on to transplant or receive 9 further cycles of the combination therapy (if transplant ineligible). In this case assessments will be performed after 6, 9 and 12 cycles.
Patients with progressive disease at any time-point or stable disease after 3 cycles will be taken off study.

Studienziele

Primary objective:
• To evaluate clinical activity and tolerability of obinutuzumab in combination with venetoclax in patients with relapsed/refractory DLBCL

Secondary objectives:
• Safety: Incidence of dose-limiting toxicities of the combination treatment
• Response duration (from first documented response)
• Progression-free survival
• Overall survival
• Ability to proceed to further stem cell transplantation (assessed by number of eligible patients reaching transplant)
• Identification of genetically/biomarker defined subgroups regarding response and survival

Einschlusskriterien (Auszug)

• Patients ≥ 18 years of age
• Diffuse large B-cell lymphoma (DLBCL) with histologically confirmed relapse within 12 months after having achieved a PR or CR with initial R-anthracycline containing therapy, or with refractoriness to initial R-anthracycline containing therapy (not achieving at least a partial response)
• At least one bi-dimensionally measurable lesion on CT scan defined as > 1.5 cm in its longest dimension.
• ECOG Performance Status of 0, 1, or 2
• Adequate organ function

Öffentliche Downloads

AGMT NHL 15 Poster
Poster am OeGHO 2017



Top



HD 21

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 1500
Start: Q1 2017 | Ende: Q3 2025
Status: planned


HD21 für fortgeschrittene Stadien: Studie zur Behandlungsoptimierung der Erstlinientherapie für Patienten mit fortgeschrittenem Hodgkin-Lymphom; Vergleich von 6 Zyklen BEACOPP eskaliert mit 6 Zyklen BrECADD.

Studiendesign

Phase III, multizentrisch, randomisiert
Standardarm
6 x BEACOPP eskaliert + 30 Gy RT auf PET-positive Reste

Experimenteller Arm
6 x BrECADD + 30 Gy RT auf PET-positive Reste

Die Patienten werden nach Einschluss in die Studie in einen der beiden Therapiearme randomisiert.

Studienziele

Die Standardbehandlung des fortgeschrittenen Hodgkin Lymphoms bei erwachsenen Patienten bis einschließlich 60 Jahren ist die Behandlung mit 6 Zyklen BEACOPP eskaliert und anschließender Bestrahlung PET-positiver Reste. Diese Behandlung ermöglicht eine hervorragende Tumorkontrolle, die vermutlich nicht weiter verbessert werden kann. Nachteilig ist jedoch die ausgeprägte kurz- und langfristige Toxizität, die mit der Behandlung mit diesem aggressiven Chemotherapieregime einhergeht.

Jüngst wurden neuere Substanzen in der Behandlung des Hodgkin Lymphom erprobt, die bei Patienten mit vielen vorhergegangenen Rezidiven erstaunlich wirkungsvoll waren und eine tolerierbare Toxizität zeigten. In der targetedBEACOPP-Studie wurde nun eine dieser neuen Substanzen, das Brentuximab vedotin, mit Varianten des BEACOPP eskaliert-Schema kombiniert, um eine bessere Verträglichkeit bei gleich guter Wirksamkeit zu erreichen. Das in dieser Studie etablierte BrECADD-Schema wird nun in der HD21 Studie im Rahmen einer randomisiert-kontrollierten, multizentrischen Phase III Studie mit dem BEACOPP eskaliert-Schema verglichen.

Patienten erhalten entweder 6 Zyklen BEACOPP eskaliert oder 6 Zyklen BrECADD. Anschließend wird das bereits in vorherigen Studien etablierte Strahlentherapiekonzept durchgeführt und nur PET-positive Reste werden nachbestrahlt. Das Ziel dieser Studie ist es zu zeigen, dass die Wirksamkeit der Therapie mit BrECADD der mit BEACOPP eskaliert nicht unterlegen ist. Gleichzeitig soll aber auch gezeigt werden, dass die Therapie hinsichtlich Hämato- und Organtoxizität weniger toxisch ist.

Begleitend sind, wie schon in vorherigen Studien der GHSG, unter anderem Projekte zur Erfassung der Langzeittoxizität, der Lebensqualität. Österreichische Zentren nehmen am wissenschaftlichen Begleitprogramm nicht teil.

Einschlusskriterien (Auszug)

Wichtige Einschlusskriterien:
Histologisch gesicherte Erstdiagnose eines Hodgkin Lymphom
Patient ist therapienaiv in Bezug auf das HL
Stadium III / IV oder IIB mit einem oder beiden Risikofaktoren E-Befall und großer Mediastinaltumor
Alter: 18-60 Jahre
Vorliegen der selbst und schriftlich erteilten Einwilligung zur Studienteilnahme
Normale Organfunktion (außer HL-bedingt)

Wichtige Ausschlußkriterien:
Vor- oder Begleiterkrankungen, die eine protokollgerechte Therapie nicht erlauben
HL als Mischtumor (sog. Composite Lymphoma)
Vorliegen eines NLPHL
maligne Tumorerkrankung in den letzten 5 Jahren (Ausnahmen siehe Protokoll)
Schwangerschaft, Stillen
Mangelnde Compliance
Teilnahme an einer anderen interventionellen Prüfung, die mit der vorliegenden Prüfung interagieren könnte

Öffentliche Downloads

GHSG HD21 Poster
Poster am OeGHO 2017



Top



AGMT_MM2

Coordinating Investigator: Prof. Dr. Heinz Ludwig
Fallzahl: 140
Start: Q3 2016 | Ende: Q3 2023
Status: recruiting


A randomized Phase II, 2-armed study in transplant ineligible patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + Lenalidomide + dexamethasone (KRd) induction therapy with respect to response rates and investigating a Carfilzomib (K) monotherapy maintenance strategy

Studiendesign

This is a randomized, 2-arm phase II, multi-center study to evaluate overall response rates in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by randomization to either Carfilzomib
maintenance treatment or observation only.
The patient population will consist of adult male and female patients with newly diagnosed multiple myeloma (MM), who are not eligible for or not willing to undergo autologous stem cell transplantation.
Treatment will be discontinued in case of progressive disease, in case of no response after 4 cycles, or due to intolerance.
A safety analysis will be conducted after 10 patients completed at least two cycles of KRd or KTd.

Studienziele

Primary objective: To show non-inferiority with respect to response rates between KTd and KRd: to determine ORR in patients after receiving 9 cycles induction therapy with either carfilzomib in combination with thalidomide and dexamethasone or carfilzomib in combination with lenalidomide and dexamethasone

Secondary objectives:
• Feasibility, safety and efficady of a K monotherapy maintenance
• PR, VGPR, CR, sCR, MDR according to IMWG
• PFS of induction arm with or without maintenance
• OS of patients reveiving either KTd vs. KRd induction therapy
• Quality of Life
• Safety and tolerability of KTd and KRd

Einschlusskriterien (Auszug)

• Male or female patients ≥ 18 years
• Newly diagnosed multiple myeloma (MM), who are not eligible for or not willing to undergo autologous stem cell transplantation.
• Measurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization):
- Serum M-protein ≥0.5 g/dL, or
- Urine M-protein ≥200 mg/24 hours, or
- In subjects without detectable serum or urine M-protein, serum-free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal ĸ/λ ratio
• No prior treatment for multiple myeloma
• ECOG performance status of 0, 1 or 2
• Adequate organ and bone marrow function:
- Bilirubin <1.5 times the upper limit of normal (ULN)
- AST and ALT < 3 times the ULN
- Absolute neurtophil count (ANC) ≥ 1000/mm3
- Hemoglobin ≥ 8.0 g/dL
- Platelet count ≥ 50.000/mm3

Öffentliche Downloads

AGMT_MM2 Poster
Poster am OeGHO 2017



Top



Ro-CHOP

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 15
Start: Q2 2016 | Ende: Q4 2024
Status: recruiting


Phase III multi-center randomized study to compare efficacy and safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma
by LYSARC: The Lymphoma Academic Research Organisation in Cooperation with AGMT

Studiendesign

This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) romidepsin administered IV at day 1 and day 8 in combination with CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.

Studienziele

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by Response Adjudication Committee (RAC).
Secondary objectives are to compare Ro-CHOP between CHOP alone in term of:
• Overall survival
• Overall Response Rate (ORR [PR+CR+CRu]) (according to the Response criteria for malignant lymphoma 1999)
• Duration of response
• Time to progression
• Time to treatment failure
• Safety
• Quality of Life (QoL)
• Response rates by PTCL histological subtypes
• Response rate by standard prognostic parameters

Einschlusskriterien (Auszug)

1. Males and females of 18 years of age to 80 years of age.
2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Patients with histologically proven peripheral T-cell lymphoma (PTCL), not previously treated; the following subtypes as defined by the WHO classification (2008;2011) may be included, whatever the Ann Arbor stage (I - IV):
a. Nodal types:
i. PTCL, not otherwise specified
ii. Angioimmunoblastic T-cell lymphoma
iii. Anaplastic large cell lymphoma, ALK-negative type
b. Extra-nodal types:
i. Enteropathy-associated T-cell lymphoma
ii. Hepato-splenic T-cell lymphoma
iii. Subcutaneous panniculitis-like T-cell lymphoma
iv. Primary cutaneous gamma-delta T-cell lymphoma
v. Primary cutaneous CD8+ aggressive epidermotropic
lymphoma
vi. Primary cutaneous CD4+ small/medium T-cell lymphoma
c. Other non classifiable peripheral T-cell lymphoma
5. ECOG performance status 0, 1 or 2
6. Negative pregnancy test for females of childbearing potential (FCBP)
7. Female patients of child bearing potential must use an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) during treatment period and 1 month thereafter; Males must use an effective method of birth control during treatment period and 3 months thereafter.
8. Life expectancy of ≥ 90 days (3 months)

Öffentliche Downloads

Ro-CHOP Poster
Poster am OeGHO 2017



Top



AGMT_SAKK 41/14 ACTIVE-2

Coordinating Investigator: Prof. Dr. Josef Thaler
Fallzahl: 542
Start: Q2 2016 | Ende: Q3 2026
Status: recruiting


Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled phase III trial

Studiendesign

All patients will undergo standard systemic therapy for metastatic colorectal cancer. Patients in the care-as-usual group are not actively encouraged to change their physical activity level e.g. to start a fitness program during chemotherapy.

The physical exercise ACTIVE-program describes a 12-week exercise program consisting of a combination of a bi-weekly aerobic exercise (cycle ergometer) supervised by a physical therapist and a self-paced increase in physical activity during daily life using a pedometer with a daily step goal as a motivational tool. The program will be individually tailored to each patient based on the training protocol and is aimed at increasing physical activity levels and cardiorespiratory fitness.

Studienziele

To assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r—Edmonton Symptom Assessment System) in patients with metastatic colorectal cancer.

Einschlusskriterien (Auszug)

• Written informed consent according to ICH/GCP regulations before randomization.
• Patient with histologically or cytologically confirmed colorectal carcinoma (CRC) required to start palliative first-line systemic therapy for inoperable or metastatic disease.
• Patients who were diagnosed with histologically or cytologically confirmed non-metastatic CRC earlier and now relapsed with metastatic disease are also eligible, if any prior neoadjuvant or adjuvant chemotherapy has been completed more than 4 months before inclusion into this trial.
• Patient has measurable disease on CT scan or MRI to be performed within 4 weeks before randomization (measurability criteria according to RECIST 1.1 [1], non-nodal lesions ≥ 10mm, lymph nodes ≥ 15mm OR evaluable disease i.e. patient with nonmeasurable metastases but elevated serum tumor-marker (CEA at least >2xULN).
• Command of written and spoken language allowing for informed consent and for filling in trial questionnaires.
Baseline patient-reported outcomes (PROs) have been completed.
• WHO performance status 0-2.
• Age 18-75 (80) years (if WHO is 0-1 upper age limit is 80 years)

Öffentliche Downloads

AGMT_SAKK 41/14 ACTIVE-2 Poster
Poster am OeGHO 20167



Top



AGMT_HNO_PN

Coordinating Investigator: Prof. Dr. Felix Keil
Fallzahl: 154
Start: Q3 2016 | Ende: Q3 2021
Status: planned


Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin

Studiendesign

Bei Patienten mit Plattenepithelkarzinomen des Kopfes und Halses stellt der Gewichtsverlust während einer Radiotherapie ein relevantes klinischen Problem dar und kann zu mehr therapieabhängigen Nebenwirkungen und eventuell auch zu einem Abbruch der potentiell kurativen Behandlung führen. Es wird davon ausgegangen, dass es bei etwa 60% der Patienten unter Radiotherapie ohne ergänzender parenteraler Ernährung zu einem kritischen Gewichtsverlust kommt.

Deshalb soll im Rahmen dieser multizentrischen, randomiserten Phase III Studie die Effizienz arenteraler Ernährung über Nacht in Bezug auf einen kritischen Gewichtsverlust von mehr als 5% zur Ausgangssituation geprüft werden.

Studienziele

Primärer Studienendpunkt:
• Kritischer Gewichtsverlust von >5% nach Radiotherapie (RTX) im Vergleich zum Ausgangsgewicht vor Radiotherapie

Sekundäre Studienendpunkte:
• Bioelektrische Impedanzanalyse (Phasewinkelreduktion >10%)
• mGPS, CCI, Lebensqualität,
• PEG-Sondenverwendung, Schluck– und Essverhalten
• Toxizität während RTX, Dosis und Dosisintensität RTX
• Progessionsfreies Überleben (PFS)
• Kachexieparameter (optional): Untersuchung von Serum Lipidpara mentern, Zytokinen, Adipöse Triglyzerid Lipase (ATGL) Aktivität in Fettgewebe

Einschlusskriterien (Auszug)

• Histologisch bestätigtes, lokal fortgeschrittenes Plattenepithelkarzinom des Larynx, Hypopharynx, Oropharynx oder der Mundhöhle mit definitiver, kurativer RTX mit Cetuximab oder Cisplatin
• p16 Status verfügbar
• Alter ≥ 18

Öffentliche Downloads

AGMT_HNO_PN Poster
Poster am OeGHO 2017



Top



AGMT_MBC-10

Coordinating Investigator: Prof. Dr. Richard Greil / PROTOCOL CONTACT: Dr. Rinnerthaler, Dr. Gampenrieder
Fallzahl: 54
Start: Q2 2016 | Ende: Q2 2019
Status: recruiting


Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA)

Studiendesign

Subjects meeting all inclusion criteria will be enrolled receiving ixazomib on days 1, 8, and 15 in combination with carboplatin on days 1, 8, and 15. Cycles will be repeated every four weeks.

Phase I:
The phase I part of this study uses an alternate dose escalation accelerated titration design. In the accelerated dose-escalation phase a single-patient cohort per dose level will be enrolled, until one dose limiting toxicity (DLT) or 2 moderate toxicities are observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.
DLTs are defined as inability to deliver the drug combination of ixazomib and carboplatin due to drug related toxicity :
• grade 3 or 4 non-hematologic toxicity excluding alopecia
• polyneuropathy greater or equal grade 3
• neutropenia grade 4 for more than 7 days
• neutropenia grade 4 with fever greater than 38.5C
• thrombocytopenia grade 4
• thrombocytopenia grade 3 with bleeding
Moderate toxicities are defined as:
• any grade 2 non-hematologic toxicity excluding alopecia
• any grade 3 hematologic toxicity
The maximum-administered dose (MAD) is defined as the dose at which DLT occur in at least two of six patients treated at that dose level. The dose just below the MAD is considered the maximum-tolerated dose (MTD), providing that DLT is observed in fewer than two of six treated patients (or fewer than one third if more than six patients will be treated) at that dose level. Determination of MAD and MTD is based on DLT observed during the first treatment cycle.

Phase II:
After establishing MTD in phase I, accrual continues to evaluate the efficacy and safety of the combination. A total of 35 patients will be included (patients enrolled in the phase I part within the conventional dose escalation phase at the dose level considered as the MTD may be included).

All subjects will continue on study drugs until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.

Studienziele

Primary endpoints
• Phase I: Determination of maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs)
• Phase II: Overall response rate (ORR)

Secondary endpoints
• Safety profile
• Overall response rate
• Clinical benefit rate
• Progression-free survival (PFS)
• Quality of Life (EORTC QLQ-C3)

Einschlusskriterien (Auszug)

Each patient must meet all of the following inclusion criteria to be enrolled in the study:
• Signed informed consent prior to any study-specific procedure
• Female patients, age ≥ 18 years
• Women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception during the study and for a period of 90 days following the last administration of study drug
• Metastatic or locally advanced (without curative loco-regional treatment options with curative intention) adenocarcinoma of the breast, histologically confirmed
• Triple negative subtype defined as the absence of staining for estrogen receptor (IHC <1%), progesterone receptor (IHC <1%) and HER2/neu (IHC 1+ or ISH ratio of < 2.0 between Her2 gene copy number and centromere of chromosome 17 or a copy number of 4 or less)
• At least one prior line of chemotherapy for metastatic or locally advanced disease or disease progression within 12 months of completion of adjuvant chemotherapy
• Documented disease progression
• At least one measurable lesion according to RECIST 1.1 criteria
• Life expectancy of at least 12 weeks
• Performance status ECOG 0-2
• Adequate left ventricular ejection fraction at baseline, defined as LVEF ≥ 50% by either echocardiogram or MUGA
• Peripheral neuropathy NCI CTCAE grade ≤ 1 or grade 2 if no pain on clinical examination
• Adequate hematological, liver and renal function

Öffentliche Downloads

AGMT_MBC-10 Poster
Poster am OeGHO 2017



Top



AGMT_ALCL1

Coordinating Investigator: Prof. Dr. Ulrich Jäger
Fallzahl: 10
Start: Q2 2015 | Ende: Q2 2021
Status: recruiting


A "window of opportunity" trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy

Studiendesign

This is an open label pilot study of combining BV in a licensed indication with imatinib in patients with ALCL. It is intended as a "window of opportunity" trial in which the study drugs will be given as an initial substitute for conventional chemotherapy with the intention to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell transplantation, if eligible.
Patients will be included in this trial if they have relapsed or refractory ALK+ ALCL after at least one line of conventional chemotherapy or if they are ineligible for conventional chemotherapy.
Imatinib will be given continuously starting from day 1 of the first cycle at an oral dose of 100mg daily. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle. BV will be given 3 weekly starting on day 1 at a dose of 1.8 mg/kg body weight. In the absence of a dose limiting toyicity (DLT) i.e. haematological toxicity ≥ grade 2, non- haematological toxicity ≥ grade 3, after 3 weeks of therapy, and in the presence of a clinical response (CR or PR) after cycle 1, the BV dose will continue every 3 weeks for 48 weeks. (Figure 2) Dose modifications and stopping rules will be introduced as described in chapter 6. In case of progression at any time during the study the patient will go off trial and receive salvage treatment.

Studienziele

Primary objective:
To determine the safety and tolerability of simultane-ous administration of brentuximab vedotin and imatinib mesylate in substitution of conventional chemotherapeutic treatment.

Secondary objective:
Clinical response rate (ORR, CR, PR) Ability to receive further treatment (stem cell trans-plantation) Progression-free survival and overall survival Identification and assessment of biomarkers

Einschlusskriterien (Auszug)

• Patients ≥ 18 years of age
• ALK+ ALCL
• Histologically confirmed relapse after having achieved a PR or CR with conventional therapy
• Refractoriness to conventional chemotherapy (SD or PD after conventional chemotherapy)
• Not able to receive conventional chemotherapy (e.g. due to comorbidities)
• Adequate organ function
• Written, voluntarily signed informed consent

Öffentliche Downloads

AGMT_ALCL1 Folder
Brief description of the Study

AGMT_ALCL1 Poster
Poster am OeGHO 2017



Top



AGMT_MM-1/ EMN-13

Coordinating Investigator: Prof. Dr. Heinz Ludwig
Fallzahl: 77
Start: 09.04.2015 | Ende: Q2 2019
Status: recruiting


Ixazomib in Combination with Thalidomide – Dexamethasone in patients with relapsed and/or refractory multiple myeloma

Studiendesign

This is an open phase II, single-arm, multi-center study to evaluate progression free survival in patients receiving ixazomib in combination with thalidomide and dexamethasone (ITD) followed by an ixazomib maintenance phase of a maximum period of 12 months.
The patient population will consist of adult male and female patients with multiple myeloma (MM) with relapsed and/or refractory disease after at least one prior treatment line.
In case of enrollment patients will receive ixazomib 4.0mg at days 1, 8, 15, thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), and dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle. The proposed number of cycles is 8. Treatment will be discontinued in case of progressive disease or in case of no response after 4 cycles (≤ SD after 4 cycles). After discontinuation of therapy an end of treatment visit (EOT) will be performed within 14 days after the last dose of the last combination treatment cycle.
After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months. Patients who completed less than 8 cycles of ITD treatment do not qualify for maintenance phase.
Follow-up visits will be performed in 3-monthly intervals until the last patient on ixazomib maintenance therapy has concluded or discontinued the maintenance phase.
A safety analysis will be conducted after enrollment of the first 6 patients and completion of at least two cycles in every patient.

Studienziele

Primary
• To determine progression-free survival in patients with relapsed/refractory multiple myeloma receiving ixazomib in combination with thalidomide and dexamethasone for 8 cycles followed by an ixazomib maintenance phase of a maximum period of 12 months.

Secondary
• To determine overall response rate (ORR) in patients with relapsed/refractory multiple myeloma receiving ixazomib in combination with thalidomide and dexamethasone followed by an ixazomib maintenance phase of a maximum period of 12 months. ORR will be assessed according to International Myeloma Working Group (IMWG) criteria, including Minor Response (MR) according to European Society for Blood and Bone Marrow Transplantation (EBMT) criteria
• To determine Overall Survival (OS) in patients with relapsed/refractory multiple myeloma receiving ixazomib in combination with thalidomide and dexamethasone followed by an ixazomib maintenance phase of a maximum period of 12 months.
• To determine renal response in a subgroup of patients with baseline GFR 15-30ml/min
• To assess safety and toxicity of the combination regimen ixazomib plus thalidomide plus dexamethasone followed by an ixazomib maintenance phase of a maximum period of 12 months.
• To assess prognostic value of risk factors at diagnosis, including clinical assessments, lab values and cytogenetic abnormalities such as translocations t(4;14), t(14;16), ampl1q, del17, del13
• To assess change of quality of life (QoL) of patients undergoing treatment with ixazomib plus thalidomide plus dexamethasone followed by an ixazomib maintenance phase of a maximum period of 12 months by use of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EORTC QLQ C30/MY-20 module
• To associate possible correlations between altered expressions of specifically selected genes including methylation status of key genes (tumor suppressor, oncogenes, DNA repair, cell cycle control and other) and their response to the treatment regimen detected by gene expression profiling and methylation assays obtained at screening

Einschlusskriterien (Auszug)

- Male or female patients 18 years or older
- Patients in need of therapy with a diagnosis of relapsed or refractory multiple myeloma who had at least one prior treatment line (induction + autologous SCT + con-solidation + maintenance therapy = 1 therapy line)
- Patients must have measurable disease defined by at least 1 of the following criteria:
•Serum M-protein ≥ 10g/l
•Urine M-protein ≥ 200mg/24h
•Serum free light chain assay: involved serum light chain ≥ 10mg/dl provided that free light chain ration is abnormal
- ECOG ≤ 2
- Disease free of prior malignancies for ≥ 2 years
- Adequate hematology, liver and renal function:
Hematologic:
ANC (absolute neutrophil count) ≥ 1.0 x 109/L
Platelets ≥ 50 x 109/L
Liver Function:
GFR ≥ 15 ml/min
Serum bilirubin ≤ 2 x ULN
AST and ALT ≤ 3 x ULN ≤ 5 x ULN if documented liver metastases
Renal Function:
Serum Creatinine ≤ 1.5 mg/dL OR Calculated Creatinine Clearance ≥ 40 mL/min

Öffentliche Downloads

AGMT_MM-1/ EMN-13 Poster
Poster am OeGHO 2017



Top



AGMT_HIV1

Coordinating Investigator: Prim. Univ.- Prof. Dr. Richard Greil
Fallzahl: 25
Start: Q2 2014 | Ende: Q3 2015
Status: geschlossen


One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Raltegravir

Studiendesign

This is a 24-week, one arm, open-label, interventional, non-comparative muticentre study to evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen after switching their boosted PI to raltegravir at standard dosage with 400mg twice daily.

Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
Patients will be assessed at baseline, after 4, 12 and 24 weeks.

Changes of ongoing antiretroviral therapy other than the switch from protease inhibitor to raltegravir during the study are strongly discouraged unless required by the study physician. In analogy for patients on lipid lowering agents, a stable regimen for 3 months prior to study entry will be required. Modifications of the lipid lowering therapy during study are discouraged and will lead to exclusion (except reduction due to amelioration of the lipid profile).

Studienziele

The objective of the study is to assess the change of lipid profiles, observed in HIV infected women with hyperlipidemia after switch from boosted protease inhibitors to raltegravir.

Einschlusskriterien (Auszug)

• Documented HIV-1 infection in female patients, age ≥18 years
• Patients receiving antiretroviral therapy consisting of at least 2 antiretroviral agents other than protease inhibitor plus a ritonavir-boosted protease inhibitor (PI) including indinavir, fosamprenavir, saquinavir, lopinavir, atazanavir, tipranavir, or darunavir for at least the previous 6 months
• Plasma HIV viral load <50 copies/ml (as recommended by the EACS Guidelines) on current boosted PI containing regimen for ≥ 6 months prior to study entry
• Patients receiving prophylaxis or treatment for an opportunistic infection or malignancy may be included as long as specific laboratory requirements were met approximately 1 month prior to screening
• Fasting LDL cholesterol >130 mg/dl
• Fasting triglycerides <450 mg/dl
• For patients on lipid lowering agents, a stable regimen for the past 3 months will be required



Top



AGMT_HNO-2

Coordinating Investigator: Univ.- Prof. Dr. Felix Keil
Fallzahl: 100
Start: Q2 2013 | Ende: Q2 2020
Status: active, not recruiting


Randomisierte Phase II Pilot Studie: Induktionstherapie mit Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU gefolgt von Radioimmuntherapie mit Cetuximab bei lokal fortgeschrittenen oder inoperablen Kopf-Hals Tumoren

Studiendesign

In dieser multizentrischen randomisierten Phase-II-Studie soll die Effizienz und Toxizität von TP plus Cetuximab mit TPF verglichen werden. Sowohl im Kontrollarm als auch im Vergleichsarm wird die Radiotherapie mit Cetuximab beibehalten.

Studienziele

Es soll geprüft werden, ob bei gleichbleibender Effizienz in einer taxanhältigen Induktionschemotherapie auf das 5FU verzichtet werden kann, da diese Substanz neben den Platinen ein erhebliches Potential für Schleimhauttoxizität hat. Speziell die Kombinationstherapie mit Docetaxel und Platinen ist im metastasierten Setting auch in Kombination mit Cetuximab hocheffektiv. Somit wäre eine Kombinationstherapie ohne 5FU für Patienten mit fortgeschrittenen HNO Tumoren eine sinnvolle Alternative.

Einschlusskriterien (Auszug)

• Histologisch bestätigtes, lokal fortgeschrittenes Plattenepithelkarzinom des Larynx, Hypopharynx, Oropharynx oder der Mundhöhle im Stadium III und IV
• In zumindest einer Ebene messbare Läsion (CT oder MR, das gewählte Verfahren muss beibehalten werden)
• Performance Score ECOG 0 - 1
• Einverständnis des Patienten/der Patientin



Top



HD 17

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 35
Start: Q4 2012 | Ende: Q3 2015
Status: active, not recruiting


HD 17 für intermediäre Stadien: Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: (4 x ABVD + IF vs. 4 x ABVD + IN vs. 4 x EACOPP-14 + IF vs. 4 x EACOPP-14 + IN)

Studiendesign

Standardarm:
2 x BEACOPP eskaliert + 2 x ABVD + 30 Gy IF-RT, unabhängig vom FDG-PET-Ergebnis

Experimenteller Arm:
2 x BEACOPP eskaliert + 2 x ABVD für alle Patienten,
danach Stratifizierung anhand FDG-PET,
für PET-positive Patienten: + 30 Gy IN-RT,
für PET-negative Patienten: keine RT

Studienziele

Primärer Endpunkt: Progressionsfreies Überleben
Sekundäre Endpunkte: Gesamtüberleben; Ansprechraten; Toxizitäten

Einschlusskriterien (Auszug)

Therapienaives Hodgkin Lymphom, Alter 18-75 Jahre, Stadium I, IIA mit Risikofaktoren, Stadium IIB mit hoher Blutsenkungsgeschwindigkeit oder > 3 involvierten Lymphoknotenarealen

URL-Link

http://www.ghsg.org/

Webseite des Sponsors

Öffentliche Downloads

HD 17 Poster
Poster am OeGHO 2016

Folder HD 17
Zweiseitiger Folder mit Kurzinformationen über die Studie



Top



CLL9

Coordinating Investigator: Prim. Univ.-Prof. Dr. Richard Greil
Fallzahl: 10
Start: Q3 2012 | Ende: Q3 2014
Status: completed


Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of Lenalidomide and concomitant evaluation of safety and efficacy

Studiendesign

This is a non-randomized, multicenter, open-label, single arm phase II trial in patients with previously untreated CD20-positive CLL.
Eligible patients will receive lenalidomide with a backbone of FR for 6 cycles. Lenalidomide will be increased by dose steps of 5 mg every 28 days in the absence of limiting toxicity. If dose limiting toxicity ensues the patients will be treated with last tolerable dose for the remainder of the 6 treatment cycles.
The first 5 patients will start with dose level 5 mg lenalidomide and further escalating dose.
After the fifth patient is included in the study, enrolment will be interrupted until this patient has finished his first treatment cycle. A safety board will evaluate the toxicities of the first 5 patients. If there are more than 2 patients experiencing a DLT in the first treatment cycle, the starting dose will not be escalated and further 5 patients will be enrolled with a starting dose of 5 mg lenalidomide. If only 2 or less patients experience a DLT in the first treatment cycle, the next 5 patients will start the treatment with 10 mg lenalidomide.

Studienziele

Objectives of the Study
Primary endpoint:
•  Tolerability of escalated starting dose

Secondary endpoints:
•  Establishment of maximal tolerated dose (MTD) of lenalidomide in combination with FR
•  Time to MTD
•  Safety profile of the FRL combination
•  Response rates in all phases by 4-colour flow cytrometric MRD analysis
•  Risk factor analysis (FISH cytogenetics, CD38/ZAP-70 expression, mutation status)
•  Longitudinal definition of T cell subsets (including prognostic EM T cells and Treg cells) +/- PD1

Einschlusskriterien (Auszug)

•  Signed written informed consent
•  Male or female ≥ 18 years of age
•  CLL (as determined by CD23+, CD5+, CD19+)
•  Treatment indication as defined by the NCIWorkshop criteria (see appendix 5 and reference 10)
•  ECOG ≤ 2
•  No previous treatment of the CLL by chemotherapy, radiotherapy (except localized radiotherapy of 1 lymphatic area) or immunotherapy
•  Life expectancy > 6 months (except prognosis due to high risk CLL)

Female subjects of childbearing potential must:
  •  understand the potential teratogenic risk to the unborn child
  •  agree to have a medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL (including females of childbearing potential who commit to complete abstinence) details see appendix 6
  •  agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 28 days after study treatment discontinuation.

The two methods of reliable contraception must include one highly effective method and one additional effective (barrier) method. Fibronectin Cell Binding Peptide (FCBP) must be referred to a qualified provider of contraceptive methods if needed. The following are examples of highly effective and additional effective methods of contraception:
Highly effective methods:
•  Intrauterine device (IUD)
•  Hormonal (birth control pills, injections, implants)
•  Tubal ligation
•  Partner's vasectomy

Additional effective methods:
•  Male condom
•  Diaphragm
•  Cervical Cap

•  Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.
•  be informed and understand the potential consequences of pregnancy and the need to notify her study doctor immediately if there is a risk of pregnancy
•  understand the need to commence the study treatment as soon as study drug is dispensed following a negative pregnancy test
•  understand the need and accepts to undergo pregnancy testing based on the frequency outlined in this protocol
•  acknowledge that she understands the hazards and necessary precautions associated with the use of lenalidomide

Male subjects must:
•  Understand the need for the use of a condom even if he has had a vasectomy, if engaged in sexual activity with a pregnant female or a female of childbearing potential.
•  Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
•  All subjects must
•  Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
•  Agree not to share study medication with another person and to return all unused study drug to the investigator



Top



AGMT_ERCC1

Coordinating Investigator: OA Dr. Alois Lang; Dr. Thomas Winder
Fallzahl: 50
Start: Q3 2012 | Ende: Q2 2015
Status: recruiting


Biomarker directed treatment in metastatic colorectal cancer

Studiendesign

The study will consist of two parts:
•  Pre-Screening phase
•  Treatment phase for KRAS and NRAS wt patients

Pre-Screening phase:
Central Evaluation of KRAS/NRAS status and ERCC-1 gene expression will be evaluated in a central laboratory.

Treatment phase:
RAS wt patients will be treated with 6 cycles of one of the following regimens chosen for optimization based on patient characteristics (primary treatment phase). Patients with ERCC-1 < 1.7 relative gene expression of ERCC-1 over ß-actin (ERCC-1 low) will be assigned to treatment with mFOLFOX6 in combination with Cetuximab. Patients with ERCC-1 gene expression > 1.7 relative gene expression of ERCC-1 over over ß-actin (ERCC-1 high) will be assigned to treatment with FOLFIRI in combination with Cetuximab.

Studienziele

Primary objective
To assess treatment response (according to Response Evaluation Criteria In Solid Tumors [RECIST])in patients with previous untreated wt RAS advanced colorectal cancer (since protocol version 3.1, dated 25.10.2013, patients with mutant KRAS and mutant NRAS are excluded) using mFOLFOX6 or FOLFIRI and cetuximab with therapy chosen using ERCC-1 gene expression assessment.

Secondary objectives
•  Progression free survival (PFS) and overall survival (OS)
•  Description of group differences between ERCC-1 low and ERCC-1 high pat.with respect to response rate.
•  Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to KRAS and NRAS status
•  Secondary resection rate
•  Molecular markers for toxicity
•  To assess toxicity

Einschlusskriterien (Auszug)

Inclusion criteria for pre-screening phase:

•  Informed Consent
•  Untreated advanced metastatic colorectal cancer patients
•  Adequate tissue to evaluate for genotyping

Inclusion criteria for treatment phase:

Patients must fulfil all criteria listed below prior to enrolment in the study:
•  Untreated wild-type RAS metastatic colorectal cancer patients
•  Previous adjuvant therapy must have been completed > 6 months
•  Age >18 years
•  Evaluable disease with CT or MRI
•  ECOG performance status of 0-2
•  Hematologic: Absolute neutrophil count > 1,500/µL Hemoglobin >9 mg/dl; Platelet count >100,000 /µl
•  Renal: Serum creatinine <1.5 x Upper limit of normal (UPN) or estimated clearance > 30 ml/min
•  Hepatic: Serum bilirubin < 1.5 mg/dl

Öffentliche Downloads

AGMT_ERCC1 Poster
Poster am OeGHO 2017



Top



HO95/EMN02

Coordinating Investigator: Prof. Dr. Pieter Sonneveld, Prof. Dr. Heinz Ludwig (Österreich)
Fallzahl: 1500
Start: Q2 2012 | Ende: Q3 2023
Status: active, not recruiting


A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma

Studiendesign

Patients with multiple myeloma, meeting all eligibility criteria will be registered on entry and treated with 3 induction cycles with VCD, followed by Cyclophosphamide for stem cell mobilization and collection.
After induction patients will be randomized to compare two intensification regimens VMP vs. HDM (R1), except if a patient will proceed to allogenic SCT. In hospitals with a policy of double intensification, all patients will be randomized at R1 between VMP, 1 HDM and 2 HDM, in order also to evaluate 1 HDM vs. 2 HDM
After intensification treatment there will be a 2nd randomization to compare VRD consolidation vs. no consolidation (R2), followed by Lenalidomide maintenance in both arms.

Studienziele

Primary Endpoint:
• For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first)
• For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first
• For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first

Secondary Endpoints:
• Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment
• Overall survival measured from the time of registration/randomization R1/ randomization R2
Patients still alive or lost to follow up are censored at the date they were last known to be alive
• Toxicity

Einschlusskriterien (Auszug)

• Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III according to the International Staging System ISS, i.e. at least one of the CRAB criteria should be present
• Measurable disease as defined by the presence of M-protein in serum or urine, or abnormal free light chain ratio
• Age 18-65 years inclusive
• WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by co-morbid conditions)
• Negative pregnancy test at inclusion if applicable
• Written informed consent

Öffentliche Downloads

HOVON Folder
Brief description of the HOVON Study



Top



AGMT_MALT-2

Coordinating Investigator: Prof. Dr. Markus Raderer
Fallzahl: 46
Start: Q1 2012 | Ende: Q3 2014
Status: completed


Phase II trial of Rituximab plus Lenalidomide in patients with lymphoma of the mucosa associated lymphoid tissue (MALT) type

Studiendesign

This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with MALT lymphoma presenting with measureable disease.

Studienziele

Primary Endpoint:
To evaluate the clinical potential of Rituximab plus Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma

Secondary Endpoint:
To evaluate the safety of Rituximab plus Lenalidomide in this patient population.

Einschlusskriterien (Auszug)

• Histologically verified diagnosis of MALT lymphoma of any localization
• Measurable disease upon diagnosis or first or greater relapse after local therapy (including gastrectomy or any type of surgery or radiation), prior chemotherapy or HP-eradication. In addition, also patients with gastric MALT-lymphoma judged refractory to HP-eradication by a minimum follow-up of 12 months after successful HP-eradication will be included in the study. Patients with gastric MALT lymphoma and no evidence of HP-infection (as judged by histology and ultimately serology) may be enrolled immediately)
• Ann Arbor Stage I-IV
• In case of prior treatment with Rituximab, the presence of CD20 on lymphoma cells must have been demonstrated before inclusion in the trial.
• ECOG performance status of 0,1 or 2
• Age > 18 years
• Life expectancy of at least 3 months
• Patient must be able to take aspirin daily as prophylactic anticoagulation (patients intolerant to ASA (may use warfarin or low molecular weight heparin)
• Hematological test results within these ranges:
Absolute neutrophil count > 1000/µl, Platelet count > 60 x 109/L
• Adequate cardiac, renal and liver function tests (LVEF > 50%, serum creatinine < 2.5mg/dl, ALAT or ASAT < 2.5 x upper limit of normal range, alkaline phosphatase < 2.5 x upper limit of normal range, serum bilirubin < 2.0 mg/dl)
• Patient must be willing and able to comply with the protocol for the entire study duration

Female subjects of childbearing potential must:
- understand the potential teratogenic risk to the unborn child
- agree to have a medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL (including females of childbearing potential who commit to complete abstinence)
- agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 28 days after study treatment discontinuation. The two methods of reliable contraception must include one highly effective method and one additional effective (barrier) method. FCBP must be referred to a qualified provider of contraceptive methods if needed. The following are examples of highly effective and additional effective methods of contraception:

Highly effective methods:
Intrauterine device (IUD)
Hormonal (birth control pills, injections, implants)
Tubal ligation
Partner's vasectomy

Additional effective methods:
Male condom
Diaphragm
Cervical Cap
Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.

- be informed and understand the potential consequences of pregnancy and the need to notify her study doctor immediately if there is a risk of pregnancy
- understand the need to commence the study treatment as soon as study drug is dispensed following a negative pregnancy test
- understand the need and accepts to undergo pregnancy testing based on the frequency outlined in this protocol
- acknowledge that she understands the hazards and necessary precautions associated with the use of lenalidomide

Male subjects must:
Understand the need for the use of a condom even if he has had a vasectomy, if engaged in sexual activity with a pregnant female or a female of childbearing potential.
Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.

All subjects must:
Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
Agree not to share study medication with another person and to return all unused study drug to the investigator



Top



HD 16

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 35
Start: Q4 2009 | Ende: Q3 2020
Status: active, not recruiting


HD 16 für frühe Stadien: Therapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

Studiendesign

Standardarm: 2 x ABVD + 20 Gy IF-RT
Experimenteller Arm:
2 x ABVD für alle Patienten, danach Stratifizierung anhand FDG-PET
für PET-positive Patienten: + 20 Gy IF-RT
für PET-negative Patienten: Therapieende

Studienziele

Primärer Endpunkt: Progressionsfreies Überleben
Sekundäre Endpunkte:
CR-Rate
Overall Survival (OS)
Anteil der Patienten mit gutem / unzureichendem Ansprechen auf 2 Zyklen ABVD
Spättoxizitäten der Therapie
Sekundärneoplasien

Einschlusskriterien (Auszug)

• Hodgkin Lymphom
• Erstdiagnose, therapienaiv, histologisch gesichert, Alter: 18-75 Jahre
• Stadium IA, IB, IIA, IIB ohne Risikofaktor

URL-Link

http://www.ghsg.de

Webseite der GHSG

Öffentliche Downloads

Folder HD 16
Zweiseitiger Folder mit Kurzinformationen über die Studie



Top



AGMT-Capecet_PK

Coordinating Investigator: Univ. Prof. Dr. Christian Dittrich
Fallzahl: 24
Start: Q4 2011 | Ende: Q2 2013
Status: completed


Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab

Studiendesign

This study is designed as a multicentre, randomised phase II trial with 24 first-line patients with metastatic K-ras wild-type CRC patients.
Patients with histologically confirmed, K-ras wild-type CRC without previous chemo-therapy for metastatic disease will be screened for this study.
Patients will be randomized in a ratio of 1:1 into two groups:

Group A:
Capecitabine in weeks 1, 2, 4, 5, 7 and 8
Cetuximab in weeks 3 to 9
Oxaliplatin in week 7

Group B:
Capecitabine in weeks 1, 2, 4, 5, 7 and 8
Cetuximab in weeks 1, 8 and 9
Oxaliplatin in week 7

This PK study has a prospective cross over design with patients serving as their own controls to minimize problems associated with inter patient variability.

Studienziele

The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of CCB and when this regimen is given combined with OxPt.
1st objective:
investigation of a possible modulation of co-administered CETUX on the metabolic activation of CCB

2nd objective:
investigation of a possible modulation of co-administered CETUX on the metabolic activation of CCB, when administered concomitantly with OxPt

Einschlusskriterien (Auszug)

For inclusion in the study, all of the following inclusion criteria must be fulfilled:
• Signed written informed consent
• Male or female ≥ 18 years of age
• Diagnosis of histologically confirmed, K-ras "wild-type" adenocarcinoma of the colon or rectum
• Metastatic colorectal carcinoma
• ECOG ≤ 2
• Eligible for therapy with Cetuximab plus Oxaliplatin and/or Capecitabine
• Leucocytes ≥ 3.0 x 10e9/L
• Neutrophils ≥ 1.5 x 10e9/L
• Platelets ≥ 100 x 10e9/L
• Hemoglobin ≥ 8 g/dL
• Bilirubin ≤ 1.5 x ULN
• ASAT and ALAT ≤ 2.5 x ULN (≤ 5 x ULN if liver metastasis are present)
• Serum creatinine ≤ 1.5 x ULN
• Adequate contraception (male or female patients) if of childbearing or procreational potentia



Top



AGMT_Sportstudie

Coordinating Investigator: Prim. Univ.-Prof. Dr. Richard Greil
Fallzahl: 80
Start: Q1 2011 | Ende: Q3 2014
Status: completed


Randomized trial of exercise training in postmenopausal patients with hormone-receptor positive breast cancer undergoing treatment with aromatase inhibitors

Studiendesign

This is a randomized trial. It will start at one site, but after enrolment of the first 10 patients, other eligible sites can participate.

All patients will be screened for their physical ability to complete the interventional exercise program. Only patients capable and willing to take part in this study and meeting all inclusion and exclusion criteria will be randomized. Randomization will be stratified according to BMI. All patients are to receive identical counseling for ideal nutritional / life-style / physical activity.

Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable; unobserved exercise program at home.

Patients will be followed-up routinely according to the stage of their disease and medical needs. Apart from examinations in the screening phase and after 1 year as well as assessment of laboratory parameters at 3, 6 and 9 months, no additional visits outside of routine visits will be required for study participants.

Patients in Arm-2 will additionally be required to adhere to the time points of the con-trolled/observed physical activity schedule.

Studienziele

Primary objective
The primary objective of the study is the individual maximum power output in watt (Pmax) on a bicycle ergometer after 6 months of controlled or unobserved physical activity.

Secondary objectives
• Determination of feasibility of achieving 12 MET/week on an outpatient basis
• Determination of adherence/compliance of patients to
• nutritional / lifestyle / physical activity counseling in Arm 1;
• nutritional and lifestyle counseling in Arm 2
• observed physical activity on an outpatient basis in Arm 2
• continued uncontrolled/unobserved physical activity after the controlled pe-riod of 6 months
• Evaluation of the influence of controlled/observed physical activity versus lifestyle counseling only on:
• Fitness level (as measured by watt/kg at the anaerobic threshold and maximal, symptom-limited excertion
• Quality of Life (as assessed by EORTC QLQ C30 plus BR-23); Life style changes; Sports habit changes
• Rate of infections; Weight; BMI; Body fat percentage (as measured by caliper; Laboratory parameters
• Time to retreatment, relapse rate and OS in the long run


Einschlusskriterien (Auszug)

• Signed informed consent
• Postmenopausal women with hormone Rec.pos. breast cancer, who are treated with aromatase inhibitors
• Patients must be able and willing to fill out repeated questionnaires on QOL.
• on lifestyle and sports habits, as well as to adhere to the physical activity program
• Patients must fulfill all screening criteria
• ECOG performance status <= 2
• all age groups



Top



SAKK 75/08

Coordinating Investigator: Prim. Univ.- Prof. Dr. Wolfgang Eisterer
Fallzahl: 300
Start: Q2 2011 | Ende: Q2 2014
Status: active, not recruiting


Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma.

Studiendesign

An open-label phase III trial

Studienziele

Primary endpoint:
· Progression-free survival
Secondary endpoints:
· Progression-free survival after surgery
· Adverse events according to CTCAE version 4.0 and major postoperative complications
· Pathological remission (=TRG 1+2)
· R0-resection
· Overall survival
· Time to loco-regional failure after R0-resection
· Time to systemic failure after R0-resection
· Feasibility of the therapy: Completion of therapy
· In-hospital mortality
· Compliance with radiotherapy standards

Einschlusskriterien (Auszug)

· Histologically confirmed squamous cell carcinoma (including basaloid-squamous cell and
adenosquamous carcinoma) or adenocarcinoma of the thoracic esophagus or the esophagogastric
junction (from 5 cm below the entrance of the esophagus into the thorax to the gastric cardia
(=esophagogastric junction), types l and II according to the Siewert classification).
· Resectable, locally advanced disease (the stage is determined by the combination of CT scan,
EUS and PET and by a multidisciplinary team discussion): T2 N1-3 or T3 Nany or T4a Nany if
technically resectable with curative intent (R0) as decided by a multidisciplinary team discussion
· Health status: WHO performance status ≤ 1
· Patient is considered operable (appropriate organ functions)

URL-Link

http://sakk.ch/de/

Öffentliche Downloads

Folder SAKK 75/08
aktueller Folder nach Amendment 3



Top



REMARC

Coordinating Investigator: Prof. Dr. Ulrich Jäger
Fallzahl: 40
Start: Q2 2010 | Ende: Q3 2017
Status: active, not recruiting


Double blind randomized phase III study of Lenalidomide (Revlimid®) maintenance versus Placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line

Studiendesign

This study is a multicenter randomized phase III study of lenalidomide (Revlimid®)
maintenance versus placebo
administered daily for 3 weeks followed by one week rest
for 24 months (26 cycles) in patients responding to R-CHOP/R-COMP for a CD20+ DLBCL.

Patients should have received at least 6 cycles of R-CHOP/R-COMP regimens and up to 8 cycles of
R-CHOP/R-COMP repeated every 2 or 3 weeks according to local preferences.

Studienziele

The primary objective is to determine the benefit estimated by the progression-free
survival associated with lenalidomide maintenance compared to placebo in responding
patients treated in first line with R-CHOP or R-COMP for diffuse large B-cell lymphoma

The secondary objectives are to assess:
- percentage of patients who convert from PR to CR
- efficacy according to the response to R-CHOP/R-COMP
- Overall survival in both groups of patients (with and without lenalidomide maintenance)
- Safety of lenalidomide in maintenance-CHOP/COMP in first line

Einschlusskriterien (Auszug)

For patients registered at the time of initial diagnosis:
• Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL)
(WHO classification 2008) including clinical subtypes (primitive mediastinal,
intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade
lymphoma (Follicular, other..) may also be included. Patients with DLBCL
associated with some small cell infiltration in bone marrow may also be included
- Or CD20+ B-cell lymphoma with intermediate features between DLBCL and
Burkitt or with intermediate features between DLBCL and classical Hodgkin
lymphoma
- Or CD20+ Follicular lymphoma grade 3B
- Or CD20+ Agressive B-cell lymphoma unclassifiable
Previously untreated with chemo- or radiotherapy

For patients registered after response evaluation to first line treatment with R-CHOP/R-COMP:
• same as above
• Have reached a CR or PR (Cheson 2007) after first line treatment with at
least 6 cycles of R-CHOP/R-COMP-14 regimens and up to 8 cycles of R-CHOP/R-COMP-21
Previously untreated with Radiotherapy

For all patients:
Aged from 60 to 80 years at time of registration
aaIPI >=1 at time of initial diagnosis



Top



Gastric 4

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 43
Start: Q1 2010 | Ende: Q2 2012
Status: geschlossen


A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab (Pmab) in KRAS wild type, resectable type II gastric adeno-carcinoma

Studiendesign

Open-label multicenter two-stage phase II trial

Studienziele

Primary Endpoint:
• Efficacy: Proportion of patients with T0 and T1 disease after neoadjuvant combined chemoimmunotherapy
• Safety: Proportion of patients with grade 4 diarrhea

Secondary Endpoints:
• Histopathological response (rate of complete pathological responses)
• Overall survival after one year
• Progression free survival after one year
• Proportion of patients completing 3 treatment cycles
• Safety (NCI CTCAE v.3)

Einschlusskriterien (Auszug)

• Untreated, histologically confirmed, KRAS wild type, resectable gastric or esophageal adenocar-cinoma
• T2-4 NX M0 disease
• ECOG performance status 0 or 1



Top



AGMT_CMML 1

Coordinating Investigator: Prof. Dr. Josef Thaler/ OA Dr. Sonja Burgstaller
Fallzahl: 30
Start: Q1 2010 | Ende: Q1 2015
Status: geschlossen


A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia

Studiendesign

This is a phase I/II, open-label, dose-escalation study of lenalidomide in patients with CMML. In phase I of the study the primary purpose is to determine the MTD. A total of 30 patients is planned to be included. Pretreatment is permitted.

Studienziele

Phase I trial:
Primary objectives:
The primary objective of the phase I trial is to determine the MTD (maximum tolerated dose) of lenalidomide.
Secondary objectives:
Secondary objectives include the evaluation of safety and tolerability.

Phase II trial:
Primary objectives:
The primary objective of the phase II trial is to determine the hematologic response achieved with lenalidomide administered in subjects at the MTD determined in phase I.
Secondary objectives:
The secondary objectives focus on achieving transfusion independence and cytogenetic response. In addition, progression free survival and overall survival will be
determined.

Einschlusskriterien (Auszug)

CMML according to the WHO diagnostic criteria
All previous cancer therapy must have been discontinued at least 4 weeks prior to treatment in this study. Patients carrying a somatic mutation involving the platelet derived growth factor receptor beta (PDGFRB) can be included if standard treatment with imatinib failed.
No prior use of lenalidomide.



Top



AGMT_NSCLC 1

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 40
Start: Q1 2010 | Ende: Q4 2011
Status: completed


Phase II Study to Investigate the Treatment of Patients with NSCLC Stage IIIB and IV without the Option of Surgery with a Combination of Cisplatin, Docetaxel and Bevacizumab

Studiendesign

This is a non-randomized, multicenter, open-label, single-arm Phase II study in patients with previously untreated inoperable NSCLC stages IIIB and IV.

Studienziele

Primary endpoint
The primary objective of this proof-of-concept study is to determine the objective response rate of patients treated within the study protocoll. This response rate will be compared to historical data from the ECOG4599 and AVAiL trials.
Secondary endpoints
Progression free survival, defined as the duration of time from first study treatment until progression or death from any cause as documented by the investigator.
Overall survival; Duration of response; Overall toxicity according to NCI-CTC criteria.

Einschlusskriterien (Auszug)

Histologically or cytologically documented inoperable, locally advanced (Stage IIIB with supraclavicular lymph node metastases or malignant pleural or pericardial effusion), metastatic (Stage IV) or recurrent NSCLC other than squamous cell (i.e. adenocarcinoma or large-cell carcinoma, tumours of mixed histology should be categorized by the predominant cell type)
At least 1 measurable lesion according to RECIST criteria
No previous neoadjuvant/adjuvant chemotherapy or previous radiotherapy



Top



CLL-8/A Mabtenance

Coordinating Investigator: Prof. Dr. Richard Greil, Doz. Dr. Alexander Egle
Fallzahl: 256
Start: Q4 2009 | Ende: Q4 2015
Status: active, not recruiting


MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia

Studiendesign

Phase III, randomized CLL Patients with a PR or CR after a Rituximab containing induction treatment will be randomized to treatment with Rituximab every 3 months for 24 months or observation for 24 months

Studienziele

Primary Endpoint: Progression free survival

Secondary Endpoints: MRD-progression free survival, conversion rate to MRD negative, median MRD levels, conversion rate to CR, effect of MRD levels on clinical PFS and OS, Event free survival, Time to next treatment, overall survival, safety, benefit according to cytogenetic risk group

Einschlusskriterien (Auszug)

• B-CLL
• ECOG performance status 0-2
• Previous Rituximab containing induction treatment of the CLL in 1st or 2nd line
• Patient must be in complete remission or partial remission after an induction treatment containing rituximab
• ANC (absolute neutrophil count) ≥ 1.0 x 109/L
• Life expectancy > 6 months

URL-Link

http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/abstract

Link zum Abstract in The Lancet Haematology



Top



PTCL 1

Coordinating Investigator: OA Dr. Georg Hopfinger
Fallzahl: 20
Start: Q3 2009 | Ende: Q2 2013
Status: completed


Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin Lymphoma (PTCL)

Studiendesign

Non-randomised, open, Phase I/II in a 3+3 design

Studienziele

Primary objective:
• To determine the maximum tolerated dose of the Lenalidomide, Vorinostat, and Dexamethasone combination

Secondary objectives:
• To determine the safety of the combination regimen, the remission rate of a combination therapy with Lenalidomide, Vorinostat and Dexamethasone, the median progression free survival, overall survival

Einschlusskriterien (Auszug)

• Patients with relapsed PTCL according to WHO classification who have received max. two previous treatments for PTCL or patients with primary refractory PTCL after one previous treatment for PTCL.
• PTCL according to WHO classification as described below:
Peripheral T-cell lymphoma, unspecified (PTCL NOS)
Angioimmunoblastic T-cell lymphoma
Primary systemic, alk negative anaplastic large cell lymphoma (T or null lymphoma)
Enteropathy-type T-cell lymphoma
Subcutaneous panniculitis-like T-NHL
Hepatosplenic  T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
• Age ≥ 18 years.
• Adequate bone marrow function i.e. absolute neutrophile count of > 1000/μl and thrombocytes > 75,000/μl.
• Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN)
Life expectancy > 6 months
• ECOG performance status 0-2
• CIRS score ≤ 6
• Ability and willingness to adhere to antithrombotic prophylaxis



Top



NHL 7-2008/A

Coordinating Investigator: Prim. Univ.-Doz. Dr. Michael A. Fridrik (für Österreich)
Fallzahl: 40
Start: Q3 2009 | Ende: Q3 2017
Status: active, not recruiting


Prospektiv randomisierte Studie zur Therapieoptimierung (Primärtherapie) fortgeschrittener progredienter follikulärer und anderer niedrig maligner sowie Mantelzell Lymphome

Studiendesign

Prospektiv randomisierte multizentrische Phase III Studie
NUR MEHR FÜR MORBUS WALDENSTRÖM PATIENTEN OFFEN!

Studienziele

Bei den follikulären Lymphomen:
Ermittlung und Vergleich des progressionsfreien Überlebens beider Therapien Bendamustin plus Rituximab und 2 Jahre Rituximab Erhaltungstherapie vs. Bendamustin plus Rituximab und 4 Jahre Erhaltungstherapie

Bei den anderen Lymphomen Immunozytom, Marginalzonen-, Mantelzell:
Ermittlung und Vergleich des progressionsfreien Überlebens beider Therapien Bendamustin plus Rituximab ohne Erhaltungstherapie versus Bendamustin plus Rituximab und 2 Jahre Rituximab Erhaltungstherapie

Einschlusskriterien (Auszug)

Patienten mit histologisch verifiziertem CD20+ C-Zell-Lymphomen folgender Entitäten:
a) Follikuläres Lymphom Grad 1 und 2
b) Lymphozytoplasmatisches Lymphom/Immunozytom (Morbus Waldenström) und kleinzelliges lymphozytisches Lymphom (CLL ohne leukämisches Blutbild)
c) Marginalzonen Lymphom, nodales und generalisiertes (nodal und extranodal)
d) Mantelzell Lymphom

URL-Link

http://www.stil-info.de/

Link zur offiziellen Webseite der StiL-Studiengruppe

Öffentliche Downloads

NHL 7-2008/A Poster
Poster am OeGHO 2016



Top



Gastric 3

Coordinating Investigator: Prof. Dr. Ewald Wöll
Fallzahl: 40
Start: Q3 2009 | Ende: Q2 2011
Status: active, not recruiting


Phase II study of Oxaliplatin/ Irinotecan/ Bevacizumab followed by Docetaxel/ Bevacizumab in inoperable locally advanced or metastatic gastric cancer patients

Studiendesign

Non-randomised, open, Phase II study

Studienziele

Primary endpoint: Response rate (RECIST)
Secondary endpoints: Toxicity (CTC 2.0); Progression-free survival time; Overall survival time

Einschlusskriterien (Auszug)

Patients with histologically proven gastric cancer, inoperable locally advanced disease or metastatic with no previous pallative chemotherapy and/ or immunotherapy



Top



CLL-6 BendAlem

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 20
Start: Q1 2009 | Ende: Q2 2013
Status: completed


Bendamustin + Alemtuzumab bei vorbehandelter chronisch lymphatischer Leukämie (CLL) – eine Phase I/II Studie mit konkomitanter Evaluierung der Sicherheit und Wirksamkeit

Studiendesign

Non-randomized phase I/II Gehan design.

Studienziele

Primärer Endpunkt: Complete Response Rate
Sekundäre Endpunkte: Sicherheit; Analyse biomarker; Quality of Life

Einschlusskriterien (Auszug)

Vorbehandeltes CLL mit Behandlungsindikation gemäß NCI Kriterien; Alter 18 Jahre und älter; ECOG 0 -2



Top



MBC 5

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 30
Start: Q1 2009 | Ende: Q2 2012
Status: completed


Lapatinib plus Caelyx in patients with advanced or metastatic breast cancer following failure of Trastuzumab therapy – a Phase II study

Studiendesign

This is a non-randomized, multicenter, open-label, single-arm Phase II study in patients with previously treated metastatic breast cancer. Eligible patients may have no more than 1 line of palliative treatment, however prior therapies must include trastuzumab containing regimens in the adjuvant or metastatic setting

Studienziele

Primary Endpoint: to determine the efficacy of a Lapatinib plus Caelyx combination regimen in the treatment of advanced metastatic breast cancer, in terms of overall response rates

Secondary Endpoint: overall survival, progression free survival, clinical benefit, to evaluate Quality of Life (QoL)

Einschlusskriterien (Auszug)

• Female patients, age ≥ 18 years.
• Advanced or metastatic breast cancer, histologically confirmed
• Documented HER2 overexpression
• At least one measurable lesion according to RECIST criteria.
• Documented disease progression
• Patients that are progredient after Trastuzumab therapy (paliativ or adjuvant)
• Life expectancy of at least 12 weeks
• Performance status 0-1
• Adequate hematology, liver and renal function



Top



AGMT_ECa

Coordinating Investigator: Prof. Dr. Eisterer
Fallzahl: 50
Start: Q2 2008 | Ende: Q4 2012
Status: completed


Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinom

Studienziele

Primärer Endpunkt: Evaluierung der Durchführbarkeit und Sicherheit einer Induktionschemotherapie und Chemoradiotherapie; Evaluierung des objektiven Tumoransprechens; Pathologische Vollremission; Operabilität
Sekundäre Endpunkte: Evaluierung der Toxizität (NCI Toxizitätskriterien); Evaluierung der Lebensqualität (EORTC Fragebogen)

Einschlusskriterien (Auszug)

Histologisch gesichertes Ösophaguskarzinom (Plattenepithelkarzinom); Messbare, nicht metastasierte Erkrankung (uT2-4); Keine Vorbehandlung (Chemotherapie, Radiotherapie oder Chirurgie)



Top



HD 18

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q3 2008 | Ende: Q2 2020
Status: active, not recruiting


HD 18 für fortgeschrittene Stadien Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

Studiendesign

Nach Amendment 2 wurde der experimentelle Arm B mit Rituximab für PET-positive Patienten nach 2 Zyklen BEACOPPesc. geschlossen (Fallzahl erreicht).

Auf Grund von Auswertungen der HD 15 Studie wurde die Standardtherapie von 8 Zyklen BEACOPPesc. auf 6 Zyklen BEACOPPesc. reduziert.

PET-negative Patienten werden nach 2 Zyklen BEACOPPesc. nun in 4 Zyklen vs. 2 Zyklen BEACOPPesc. randomisiert.

Studienziele

Primärer Endpunkt: Progressionsfreies Überleben
Sekundäre Endpunkte: Gesamtüberleben; Ansprechraten; Toxizitäten

Einschlusskriterien (Auszug)

Therapienaives Hodgkin Lymphom, Alter: 18-60 Jahre; Stadium IIB mit großem Mediastinaltumor oder Extranodalbefall, Stadien III - IV

URL-Link

http://www.ghsg.org/

Link zur offiziellen Webseite der GHSG



Top



ML20523_MALT

Coordinating Investigator: Prof. Dr. Markus Raderer
Fallzahl: 40
Start: Q2 2008 | Ende: Q4 2010
Status: completed


Rituximab und 2 CdA bei Patienten mit fortgeschrittenem oder refraktärem Lymphom des Mukosa-assoziierten Gewebes (MALT-Lymphom). Eine akademische, multizentrische Phase II Studie. (AGMT_MALT)

Studienziele

Primärer Endpunkt: Ansprechrate
Sekundäre Endpunkte: Sicherheit; Progressionsfreies Überleben und Relapse-free Survival

Einschlusskriterien (Auszug)

Histologisch bestätigtes MALT Lymphom mit messbaren Läsionen (Stadium I – IV), nach erstem oder wiederholtem Relapse auf HP-Eradikation, Bestrahlung oder Chemotherapie



Top



CLL-5 RevliRit

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 45
Start: Q3 2008 | Ende: Q1 2011
Status: completed


Fludarabine/ Rituximab in Kombination mit Lenalidomide gefolgt von Rituximab/ Lenalidomid bei unbehandelter chronisch lymphatischer Leukämie – eine Dosisfindungsstudie mit konkomitanter Auswertung der Sicherheit und Wirksamkeit

Studienziele

Primärer Endpunkt: Bestimmung der MTD;
Sekundäre Endpunkte: Sicherheit; Wirksamkeit; Ansprechraten; Risikofaktoren und Quality of Life

Einschlusskriterien (Auszug)

Therapiebedürftige, unbehandelte B-CLL, Alter 18 Jahre und älter, ECOG Status 0 - 2



Top



NHL-14

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 80
Start: Q4 2007 | Ende: Q2 2013
Status: completed


Multizentrische Studie über die Kardiotoxizität von R-CHOP (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednisolon) v. R-COMP (Rituximab, Cyclophosphamid, Liposomalem Doxorubicin, Vincristin und Prednisolon) bei Patienten mit diffus großzelligem B-Zell Lymphom

Studienziele

Primärer Endpunkt: Reduktion der akuten Kardiotoxizität
Sekundäre Endpunkte: Wertigkeit von seriellen NT-proBNP Messungen; Remissionsraten; Unterschiede im Überleben; Event-free Survival und Progressionsfreies Überleben nach 3 und 5 Jahren; Toxizitäten

Einschlusskriterien (Auszug)

Diffus großzelliges B-Zell Lymphom, CD 20 positiv; Messbarer Tumor nach den Internationalen Response Kriterien; alle Stadien

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/26990931

Link zum Abstract bei PubMed



Top



KRK 0504

Coordinating Investigator: Prof. Dr. Richard Greil/ AIO
Fallzahl: 120
Start: Q4 2006 | Ende: Q4 2009
Status: geschlossen


Zweitlinientherapie AIO-IRI/ FOLFIRI/ CAPIRI/ XELIRI +/- Bevacizumab bzw. FUFOX/ FOLFOX/ CAPOX/ XELOX +/- Bevacizumab bei Patienten mit metastasiertem kolorektalem Karzinom nach Progress unter Erstlinientherapie mit Fluoropyrimidin/ Oxaliplatin- Bevacizumab bzw. Fluoropyrimidin/ Irinotecan- Bevacizumab

Studienziele

Primärer Endpunkt: Progressionsfreie Zeit
Sekundäre Endpunkte: Gesamtüberlebenszeit; Remissionsraten; Toxizitäten

Einschlusskriterien (Auszug)

Histologisch gesichertes, metastasiertes und inoperables Kolorektalkarzinom, Progression auf Bevacizumab-hältige Chemoimmuntherapie innerhalb von 3 Monaten nach der letzten Bevacziumabgabe, Alter 18 Jahre und älter



Top



CLL-4 CHAIROS

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 40
Start: Q4 2005 | Ende: Q4 2007
Status: completed


FCR Chemoimmuno Induktionstherapie gefolgt von FR und Rituximab Erhaltungstherapie bei chemonaiven Patienten mit B-CLL – Eine Phase II Studie

Studienziele

Primärer Endpunkt: Complete Response Rate
Sekundäre Endpunkte: Klinische Wirksamkeit; Sicherheit; Zytogenetisches und molekulares Risikoprofil

Einschlusskriterien (Auszug)

Unbehandelte B-CLL mit Behandlungsindikation gemäß NCI Kriterien, Alter 18 Jahre und größer, ECOG 0 - 2



Top



HD 13

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q4 2003 | Ende: Q4 2009
Status: completed


HD 13 für frühe Stadien: Qualitätssicherungsprotokoll zur Toxizitätsreduktion in der Primärtherapie des frühen Morbus Hodgkin (2x ABVD+IF vs. 2x ABV+IF vs. 2x AVD+IF vs. 2x AV+IF)

Studienziele

Toxizitätsminderung durch Deeskalation der Chemotherapie bei gleichzeitiger Sicherung der hohen FFTF- und OS-Raten; Primärer Endpunkt: Freedom from Treatment Failure (FFTF)

Einschlusskriterien (Auszug)

Morbus Hodgkin, Erstdiagnose, therapienaiv, histologisch gesichert; Alter: 18-75 Jahre; Stadium IA, IB, IIA, IIB ohne Risikofaktoren

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/25539730

Link zum Abstract bei PubMed



Top



HD 14

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q4 2003 | Ende: Q4 2009
Status: completed


HD 14 für intermediäre Stadien: Qualitätssicherungsprotokoll zur Effektivitätssteigerung in der Primärtherapie des intermediären Morbus Hodgkin (4x ABVD + IF vs. 2x BEACOPP eskaliert + 2x ABVD + IF)

Studienziele

Steigerung der Wirksamkeit der Therapie; Primärer Endpunkt: Freedom from Treatment; Failure (FFTF)

Einschlusskriterien (Auszug)

Morbus Hodgkin, Erstdiagnose, therapienaiv, histologisch gesichert; Alter: 18-60 Jahre; Stadium IA, IB, IIA, IIB mit mindestens einem Risikofaktor

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/22271480

Link zum Abstract bei PubMed



Top



HD 15

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q4 2003 | Ende: Q2 2008
Status: completed


HD 15 für fortgeschrittene Stadien: Qualitätssicherungsprotokoll zur Toxizitätsreduktion und zur prognostischen Bedeutung der FDG-PET in der Primärtherapie des fortgeschrittenen Morbus Hodgkin (8x BEACOPP eskaliert vs. 6x BEACOPP eskaliert vs. 8x BEACOPP-14, gefolgt von RT auf PET positive PR)

Studienziele

Primäres Ziel: Toxizitätsminderung der Chemotherapie bei gleichzeitiger Sicherung der hohen FFTF- und OS-Raten; Primärer Endpunkt: Freedom from Treatment Failure (FFTF)
Sekundäre Ziele: Einfluss von Erythropoetin auf die Lebensqualität und die prognostische Bedeutung der FDG

Einschlusskriterien (Auszug)

Morbus Hodgkin,Erstdiagnose, therapienaiv, histologisch gesichert; Alter: 18-60 Jahre; Stadium IIB mit großem Mediastinaltumor oder Extranodalbefall, III, IV

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/22480758

Link zum Abstract bei PubMed



Top



CLL-ic NHL II

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 14
Start: Q3 1999 | Ende: Q1 2003
Status: geschlossen


Fludarabine (oral)/Interferon- Induktions Therapie und Interferon- Erhaltungstherapie bei Patienten mit B-CLL

Studienziele

Primärer Endpunkt: Response rate
Sekundäre Endpunkte: Remissionsdauer; Toxizität; Quality of Life; Immunstatus

Einschlusskriterien (Auszug)

Unbehandelte und vorbehandelte Patienten mit B-CLL oder immunozytischen Lymphomen



Top



HD 10

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q1 1999 | Ende: Q3 2002
Status: completed


HD 10 für limitierte Stadien, Studienprotokoll der Primärtherapie des Morbus Hodgkin

Studienziele

Hohe primäre Tumorkontrolle bei niedriger langfristiger therapiebedingter Toxizität.

Einschlusskriterien (Auszug)

Morbus Hodgkin, Erstdiagnose, therapienaiv, histologisch gesichert; Alter: 16-75 Jahre; Stadium IA, IB, IIA, IIB ohne Risikofaktoren

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/20818855

Link zum Abstract bei PubMed



Top



HD 11

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q1 1999 | Ende: Q2 2002
Status: completed


HD 11 für intermediäre Stadien, Studienprotokoll zur Primärtherapie des Morbus Hodgkin

Studienziele

Verringerung der Rate der Patienten mit initialem Therapieversagen;
Durch Reduktion der Strahlentherapie auf das Involved Field keine Erhöhung der gesamten Therapiebelastung.

Einschlusskriterien (Auszug)

Morbus Hodgkin, Erstdiagnose, therapienaiv, histologisch gesichert; Alter: 16-75 Jahre; Stadium IA, IB, IIA, mit Risikofaktoren, IIB mit hoher Blutsenkungsgeschwindigkeit oder > 3 involvierten Lymphoknotenarealen

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/20713848

Link zum Abstract bei PubMed



Top



CLL-ic

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 120
Start: Q3 1994 | Ende: Q3 1997
Status: geschlossen


Fludarabin- Induktions/Interferon- Erhaltungstherapie primär unbehandelter und erstrelapsierender chronisch lymphatischer Leukämien und immunocytischer NHL

Studienziele

Primärer Endpunkt: Remissionsrate, Time to Progression
Sekundäre Endpunkte: Überleben; Toxizität; Sekundärneoplasien

Einschlusskriterien (Auszug)

B-CLL oder immunocytisches Lymphom unbehandelt oder 1. Rezidiv, 20-70 Jahre



Top



02/89

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


Risikoadaptierte sequentielle Chemotherapie (+/- Erhaltungstherapie) beim metastasierenden Mammakarzinom unter besonderer Berücksichtigung der Lebensqualität. Kontinuierliche versus intermittierende Chemotherapie bei Patientinnen mit Low Risk.



Top



01/89

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


Risikoadaptierte sequentielle Chemotherapie (+/- Erhaltungstherapie) beim metastasierenden Mammakarzinom unter besonderer Berücksichtigung der Lebensqualität. Kontinuierliche versus intermittierende Chemotherapie bei Patientinnen mit High Risk.



Top



Protokoll 86

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


5FU/Leucovorin vs. 5FU/Leucovorin/IFNa2c in der Therapie des metastasierenden Kolorektalkarzinoms



Top



Protokoll 87

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


Randomisierte Multizentrische Studie zur Erfassung der Wertigkeit von IFNa als Erhaltungstherapie bei CR/ PR beim metastasierenden Kolorektalkarzinom



Top



Protokoll 89

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


Palliative Kolorektalstudie



Top



CaelNav 1st Line

Coordinating Investigator: OA Dr. Brigitte Mlineritsch
Fallzahl: 50
Start: Q4 2002 | Ende: Q2 2004
Status: geschlossen


Phase II Study of CAELYX®/Navelbine® as first line Chemotherapy in Metastatic Breast Cancer in Elderly Patients

Studienziele

Primärer Endpunkt: Response rate
Sekundäre Endpunkte: Progression free survival, time to progression and overall survival, toxicity and quality of life

Einschlusskriterien (Auszug)

Chemotherapeutisch unbehandelte metastasierte Mammakarzinome
60 Jahre oder älter



Top



Flusalem

Coordinating Investigator: Prof. Dr. Richard Greil
Fallzahl: 28
Start: Q1 2004 | Ende: Q4 2007
Status: geschlossen


Subkutanes MabCampath® (Alemtuzumab) und orales Fludara® (Fludarabinephosphate) in der Behandlung primär refraktärer oder erstrelapsierter chronisch lymphozytischer Leukämie: Eine Pilotstudie (FLUSALEM) zur Bestimmung der Sicherheit und Wirksamkeit.

Studienziele

Primärer Endpunkt: Sicherheit; Verträglichkeit und Ansprechraten
Sekundäre Endpunkte: Time to Retreatment; Time to Progression; Gesamtüberleben; Quality of Life

Einschlusskriterien (Auszug)

B-CLL mit Indikation für Zweit- oder Drittlinientherapie



Top



Gastric 1

Coordinating Investigator: Prof. Dr. Ewald Wöll
Fallzahl: 40
Start: Q4 2000 | Ende: Q2 2005
Status: geschlossen


Pilotstudie von Oxaliplatin und Irinotecan bei fortgeschrittenem Magenkarzinom

Studienziele

Primärer Endpunkt: Machbarkeit und Toxizität
Sekundärer Endpunkt: Response

Einschlusskriterien (Auszug)

Inoperables lokal fortgeschrittenes oder metastasiertes Magenkarzinom



Top



Gastric 2

Coordinating Investigator: Prof. Dr. Ewald Wöll
Fallzahl: 40
Start: Q4 2006 | Ende: Q2 2008
Status: geschlossen


Phase II Studie von Oxaliplatin/ Irinotecan/ Cetuximab in der Erstlinientherapie bei Patienten mit lokal fortgeschrittenem oder metastasiertem Magenkarzinom

Studienziele

Primärer Endpunkt: Ansprechrate
Sekundäre Endpunkte: Gesamtüberleben; Sicherheit und Progressions-freies Überleben

Einschlusskriterien (Auszug)

Histologisch gesichertes, inoperables lokal fortgeschrittenes oder metastasiertes Magenkarzinom ohne vorherige palliative Chemotherapie oder Immuntherapie



Top



GemVin 2nd Line

Coordinating Investigator: OA Dr. Renate Schaberl-Moser
Fallzahl: 35
Start: Q3 1999 | Ende: Q1 2002
Status: geschlossen


Gemcitabine/Vinorelbin als Second Line Chemotherapie beim fortgeschrittenen Mammakarzinom

Studienziele

Primärer Endpunkt: Remissionsrate
Sekundäre Endpunkte :Zeit zur Progression; Überleben; Toxizität; Lebensqualität

Einschlusskriterien (Auszug)

Metastasiertes Mammakarzinom, Versagen auf 1st line Therapie



Top



HD 12

Coordinating Investigator: Prof. Dr. Richard Greil/ DHSG
Fallzahl: 30
Start: Q3 2000 | Ende: Q4 2002
Status: completed


HD 12 für fortgeschrittene Stadien, Studienprotokoll zur Primärtherapie des Morbus Hodgkin

Studienziele

Primärer Endpunkt: Freedom From Treatment Failure (FFTF)
Sekundäre Endpunkte: Überleben, CR, Toxizität, Lebensqualität

Einschlusskriterien (Auszug)

Morbus Hodgkin, Erstdiagnose, therapienaiv, histologisch gesichert; Alter: 16-65 Jahre; Stadium IIIA, IIIB, IV mit Risikofaktoren a-d, IIB mit großem Mediastinaltumor oder Extranodalbefall

URL-Link

http://www.ncbi.nlm.nih.gov/pubmed/21990399

Link zum Abstract bei PubMed



Top



NHL-01

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 81
Start: Q4 1987 | Ende: Q1 1991
Status: geschlossen


CEOP-IMVP-Dexa bei aggressiven Non Hodgkin Lymphomen

Studienziele

Primärer Endpunkt: Remissionsrate
Sekundäre Endpunkte: Überleben; Time to Treatment Failure; Time to Relapse; Toxizität

Einschlusskriterien (Auszug)

Unbehandelte aggressive Non Hodgkin Lymphome



Top



NHL-10

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 25
Start: Q3 2003 | Ende: Q3 2005
Status: geschlossen


Multizentrische Studie über die Machbarkeit einer intensiven Chemo- Immunotherapie bei Patienten Älter als 60 Jahre mit aggressivem B-Zell Lymphom

Studienziele

Primärer Endpunkt: Machbarkeit von CHOP 14 tägig in Kombination mit Rituximab
Sekundäre Endpunkte: Überleben nach 3 und 5 Jahren; Event-free Survival nach 3 und 5 Jahren; Progression-free Survival nach 3 und 5 Jahren; Cause-specific Death; Remissionsrate; Toxizität; Rate der Sekundärmalignome

Einschlusskriterien (Auszug)

Aggressive B-Zell Lymphome, CD 20 Positiv, Alter: 60-75



Top



NHL-11

Coordinating Investigator: Prof. Dr. Johannes Drach
Fallzahl: 45
Start: Q2 2003 | Ende: Q2 2010
Status: geschlossen


Rituximab plus CHOP plus Thalidomide (R-CHOP-THAL), gefolgt von Thalidomide Erhaltungstherapie bei unbehandeltem Mantelzelllymphom

Studienziele

Primärer Endpunkt: Progressionsfreies Überleben (PFS)
Sekundäre Endpunkte: Sicherheit; Ansprechen und Gesamtüberleben

Einschlusskriterien (Auszug)

Therapienaive Patienten mit histologisch gesichertem CD 20-positivem Mantelzelllymphom



Top



NHL-12

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 30
Start: Q2 2005 | Ende: Q2 2008
Status: geschlossen


Multizentrische, offene, nicht randomisierte Phase II Studie zur Untersuchung der Wirksamkeit und Verträglichkeit der Konsolidierungstherapie mit 90Yttrium Ibritumomab Tiuxetan (Zevalin®) bei Patienten mit follikulärem Non-Hodgkin Lymphom mit Remission oder Stable Disease nach Primär- oder Sekundärtherapie mit mindestens 6 Zyklen Fludarabin/Mitoxantron mit oder ohne Rituximab

Studienziele

Primärer Endpunkt: Event-free Survival nach 3 und 5 Jahren; Toxizität nach der WHO Skala
Sekundäre Endpunkte: Progression free survival nach 3 und 5 Jahren; Disease-free Survival; Response duration nach 3 und 5 Jahren; Time to next treatment nach 3 und 5 Jahren; Überleben nach 5 Jahren; Bcl-2 Konversion von positiv auf negativ nach Konsolidierungstherapie mit 90Yttrium Ibritumomab Tiuxetan; Verbesserung der Remission 12 Wochen nach der Therapie mit 90Yttrium Ibritumomab Tiuxetan; Rate der Sekundärmalignome

Einschlusskriterien (Auszug)

Follikuläres B-Zell Lymphom (WHO Klassifikation) G I oder II (CD 20 positiv) Stadium III oder IV, CR, CRu, PR, NC nach 6 Induktionstherapien mit Mitoxantron und Fludarabin mit oder ohne Rituximab



Top



NHL-13

Coordinating Investigator: Prof. Dr. Ullrich Jäger
Fallzahl: 440
Start: Q3 2004 | Ende: Q4 2008
Status: completed


Eine randomisierte Phase III Studie von Rituximab als Erhaltungstherapie versus Beobachtung bei aggressive B-Zell Non-Hodgkin Lymphoma

Studienziele

Primärer Endpunkt: Event-free Survival (EFS)
Sekundäre Endpunkte: Quality of Life; Sicherheit; Gesamtüberleben; Subgruppenanalyse nach histologischen Subtypen

Einschlusskriterien (Auszug)

Diffus großzelliges B-Zell Lymphom oder follikuläres NHL Grad III, CD 20 positiv, Erstlinientherapie mit 8 Zyklen Rituximab und 4 bis 8 Zyklen CHOP-ähnlicher Chemotherapie und CR oder Cru als bestem Response nach Induktionstherapie



Top



NHL-02

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 53
Start: Q3 1988 | Ende: Q3 1993
Status: geschlossen


Multizentrische randomisierte Therapiestudie CVP versus CVP + α-2-Interferon bei niedrig malignen Non-Hodgkin Lymphomen

Studienziele

Primärer Endpunkt: Remissionsrate
Sekundäre Endpunkte: Überleben; Time to Treatment Failure; Time to Relapse; Toxizität

Einschlusskriterien (Auszug)

Unbehandelte niedrig maligen Non-Hodgkin Lymphome St III-IV



Top



NHL-03

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 85
Start: Q3 1991 | Ende: Q4 1994
Status: geschlossen


Randomisierte offene Phase III Studie von CEOP/IMVP-Dexa alternierender Chemotherapie plus Filgrastim versus CEOP/IMVP-Dexa alternierender Chemotherapie bei aggressivem Non-Hodgkin Lymphom

Studienziele

Primärer Endpunkt: Inzidenz der febrilen Neutropenien
Sekundäre Endpunkte: Behandlungsverzögerung; Dosisintensität; Dauer der febrilen Perioden; Tage mit Antibiotika; Tage mit Infektion; Überleben; Ansprechrate auf Chemotherapie; Time to Relapse; Time to Treatment Failure

Einschlusskriterien (Auszug)

Unbehandelte aggressive Non-Hodgkin Lymphome



Top



NHL-05

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 115
Start: Q1 1995 | Ende: Q3 2001
Status: geschlossen


Multizentrische randomisierte Studie über die Primärtherapie hochmaligner Non-Hodgkin Lymphome mit den Polychemotherapien CHOP (Cyclophosphamid, Doxorubicin, Vincristin, Prednisolon) versus CEOP/IMVP-Dexa (Cyclophosphamid, Epirubicin, Vincristin, Prednisolon, Ifosfamid, Methotrexat, VP-16, Dexamethason)

Studienziele

Primärer Endpunkt: 3-Jahres Überleben
Sekundäre Endpunkte: Remissionen; Time to Treatment Failure; Time to Relapse; Toxizität; Therapien nach einem Rezidiv

Einschlusskriterien (Auszug)

Unbehandelte aggressive Non-Hodgkin Lymphome



Top



NHL-04, 06 und 07

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 116
Start: Q2 1993 | Ende: Q1 2000
Status: geschlossen


2-chlorodesoxyadenosine (2-CdA) in der Therapie niedrig maligner Non-Hodgkin Lymphome (NHL). Amendment IL-2, Amendment Mabthera

Studienziele

Primärer Endpunkt: Remissionsrate
Sekundäre Endpunkte: Überleben; Time to Treatment Failure; Time to Relapse; Toxizität; Dauer der Immunsuppression

Einschlusskriterien (Auszug)

Unbehandelte follikuläre Non Hodgkin Lymphome Stadium III-IV



Top



NHL-08

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 25
Start: Q3 2003 | Ende: Q4 2005
Status: geschlossen


Multizentrische Studie über die Wertigkeit von Rituximab als Primärtherapie aggressiver B-Zell Lymphome bei Patienten im Alter von 60 Jahren und darunter

Studienziele

Primärer Endpunkt: Machbarkeit der Kombination CEOP/IMVP-Dexa und Rituximab
Sekundäre Endpunkte: Überleben; Event-free Survival und Progressions-freies Überleben nach 3 und 5 Jahren, Cause-specific Death, Remissionsrate, Toxizität, Rate der Sekundärmalignome

Einschlusskriterien (Auszug)

Aggressive B-Zell Lymphome, CD 20 Positiv, Alter: 18-60



Top



NHL-09

Coordinating Investigator: Doz. Dr. Michael Fridrik
Fallzahl: 25
Start: Q1 2004 | Ende: Q1 2008
Status: geschlossen


Multizentrische Studie über die Kombination von oralem Fludarabin, Mitoxantron und Rituximab Induktionstherapie und Rituximab Erhaltungstherapie bei follikulärem B-Zell Lymphom

Studienziele

Primärer Endpunkt: Konversionsrate der bcl-2 PCR im Blut und Knochenmark
Sekundäre Endpunkte: Verbesserung der Remission durch Rituximab Erhaltung; Überleben; Event-free Survival und Progressions-freies Überleben nach 3 und 5 Jahren; Cause-specific Death; Remissionsrate; Toxizität; Rate der Sekundärmalignome

Einschlusskriterien (Auszug)

Follikuläre Lymphome CD-20 positiv, St III oder IV



Top



HNO Studie: Induktions-CT + Radioimmuntherapie

Coordinating Investigator: Prof. Dr. Felix Keil
Fallzahl: 50
Start: Q3 2007 | Ende: Q4 2013
Status: geschlossen


Klinische Studie einer neuen Medizinischen Methode durch Kombination der Induktionstherapie mit TCF mit Radiotherapie und konkomitanter Immunotherapie mit Cetuximab bei lokal fortgeschrittenen oder inoperablen HNO Tumoren

Studienziele

Primäres Studienziel: Lokoregionäre Kontrolle nach einem Jahr. Es ist dies die Zeit vom Studienbeginn bis zur ersten dokumentierten lokoregionären Progression oder bis zum Auftreten eines lokoregionären Rezidivs.
Sekundäre Studienziele: Ansprechrate der gesamten Therapie (CR, PR, PD, SD) (Kriterien nach RECIST siehe Anhang); Akuttoxizität bis 3 Monate nach Radiotherapie; Spättoxizität bis 60 Monate nach Studienbeginn; Progression-free survival, Overall survival

Einschlusskriterien (Auszug)

Histologisch bestätigtes lokal fortgeschrittenes Plattenepithelkarzinom des Larynx, Hypopharynx, Oropharynx oder der Mundhöhle im Stadium III und IV; in zumindest einer Ebene messbare Läsion (CT oder optional PET-CT); Performance Score ECOG 0-1



Top



MinT Follow-Up

Coordinating Investigator: Prof. Dr. Jäger/ DSHNHL
Fallzahl: 11
Start: Q1 2008 | Ende: Q2 2008
Status: geschlossen


Follow-up observational study of the randomised intergroup trial of first line treatment for young good-prognosis diffuse large B-Cell non-Hodgkin lymphoma patients with a CHOP-like chemotherapy regiment with or without the anti-CD20 antibody Rituximab (IDEC-C2B8)

Studienziele

Primary end point: TTF (time to treatment failure)
Secondary end points: rate of complete remissions,; rate of primary progressions; tumor control; disease free survival; relapse rate; preogression free, relapse free and overall survival; long term toxicities; second neoplasms

Einschlusskriterien (Auszug)

All patients previously enrolled in the MinT Study



Top



Vin Mono

Coordinating Investigator: OA Dr. Brigitte Mlineritsch
Fallzahl: 57
Start: Q1 1991 | Ende: Q1 1994
Status: geschlossen


Vinorelbine in der Behandlung des metastasierenden Mammakarzinoms

Studienziele

Ermittlung der Remissionsrate
Evaluierung der Toxizität einer Vinorelbine-Monotherapie

Einschlusskriterien (Auszug)

Histologisch bestätigtes metastasierendes Mammakarzinom
Messbarer Tumor
Letzte Chemo- oder Hormontherapie mindestens 4 Wochen zurückliegend und bestehende PD
1st Line Patienten mit Vorbehandlung



Top



GemVin 1st Line

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


Gemcitabine/ Vinorelbine als First Line Chemotherapie beim fortgeschrittenen Mammakarzinom



Top



CaelMono 2nd Line

Coordinating Investigator: OA Dr. Brigitte Mlineritsch
Fallzahl: 30
Start: | Ende:
Status: geschlossen


Phase II Studie zur Bewertung von Caelyx Monotherapie (Pegyliertes liposomales Doxorubicin-HCl)beim metastasierten Mammakarzinom nach Versagen einer First-Line Therapie

Studienziele

Remmissionsrate und Evaluierung der Toxizität der pegylierten liposomalen Form des Doxorubicins

Einschlusskriterien (Auszug)

Histologisch bestätigtes metastatsierendes Mammakarzinom
Vorherige palliative Chemotherapie ohne Anthracycline



Top



VinInt 2nd Line

Coordinating Investigator:
Fallzahl:
Start: | Ende:
Status: geschlossen


Second Line Therapie mit Vinorelbine und Interferon-alpha-2c bei progredienten hämatogenen metastasierenden Hypernephrom (M1)



Top



AGMT_CML 1

Coordinating Investigator: Univ.-Prof. Dr. Josef Thaler / OA Dr. Sonja Burgstaller
Fallzahl: 12
Start: 15.07.2013 | Ende: 31.12.2015
Status: recruiting


Phase 1 study to evaluate the feasibility and efficacy of the addition of P1101 (PEG-Proline-Interferon alpha-2b) to imatinib treatment in patients with chronic phase chronic myeloid leukaemia not achieving a complete molecular response (MR 4.5 or BCR-ABL transcripts not detectable)

Studiendesign

This is a phase 1, open label pilot study of adding P1101 to treatment with imatinib in patients with CML in chronic phase. Patients are eligible, if a molecular remission 4.5 or below has not been achieved with imatinib therapy alone after at least 18 months of therapy. Only patients achieving a CHR and a CCyR at study entry will be included. P1101 will be added in a dose of 50µg subcutaneously every 14 days. In the absence of a dose limiting toxicity (DLT), i.e. haematological toxicity ≥ grade 2, non haematological toxicity ≥ grade 3, after 12 weeks of therapy, P1101 will be increased to 100µg subcutaneously every 14 days (refer to 6.2.). In the absence of a DLT after another 12 weeks of therapy, treatment will be continued with the same dose level for further 12 months. A dose of 100µg every 14 days is considered as maximum dose.
Imatinib will be continued at the same dose level as before study entry.


Studienziele

Primary objective:
to determine the safety and tolerability of the addition of P1101 to the currently established dose of imatinib.
Secondary objective:
to determine the rate of achievement of ≥ 1 log reduction from the initial BCR-ABL transcript level at study entry and the achievement of molecular remission 4.5 or undetectable BCR-ABL transcripts.

Einschlusskriterien (Auszug)

• Patients ≥ 18 years of age
• BCR-ABL positive chronic myeloid leukaemia in hronic phase treated with imatinib as first line therapy
• CHR, CCyR after at least 18 months of imatinib treatment
• Adequate organ function, defined as the following:
total bilirubin < 1.5 x ULN, AST and ALT < 2.5 x ULN, creatinine < 1.5 x ULN, ANC > 1.5 x 109/L, platelets > 100 x 109/L
• Written, voluntarily signed informed consent

Öffentliche Downloads

AGMT_CML 1 Poster
Poster am OeGHO 2017



Top



AGMT MBC-6

Coordinating Investigator: Prim. Univ. Prof. Dr. R. Greil
Fallzahl: 40
Start: 06.08.2013 | Ende: 31.08.2016
Status: active, not recruiting


Capecitabine in combination with Bendamustine in women with pretreated locally advanced or metastatic Her2-negative breast cancer, a Phase II Trial

Studiendesign

This is a non-randomized, multicenter, open-label, single-arm Phase II study in pretreated patients with Her2-negative advanced breast cancer. Prior therapies must include anthracyclines and/or taxans in the adjuvant or metastatic setting. Following a two-stage design efficacy and safety of bendamustine and capecitabine will be evaluated following recruitment of the first 20 patients. Upon favorable results a further 20 patients will be recruited to reach the target population of 40 evaluable patients.


Studienziele

Primary objective:
The efficacy of a capecitabine plus bendamustine combination regimen in the treatment of Her2-negative advanced metastatic breast cancer.
Secondary objectives:
• To determine the safety profile of a combination with capecitabine and bendamustine in terms of qualitative and quantitative toxicities from first study treatment dose until completion of study treatment due to progression or for any other reason.
• To evaluate the study population with respect to the following: clinical benefit (CR, PR or stable disease for at least 24 weeks), progression free survival (from treatment start until progression or death from any cause) and explorative the overall survival (from treatment start until death from any cause).
• To evaluate Quality of Life (QoL) status within the study population is captured using the EORTC QLQ-C30 standard questionnaire
• Predefined subgroup analysis of triple-negative patients and hormone receptor positive patients in terms of response

Einschlusskriterien (Auszug)

• Signed informed consent
• Female patients, age ≥ 18 years (women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception)
• Advanced or metastatic Her2-negative breast cancer, histologically confirmed
• At least one measurable lesion according to RECIST criteria (Version 1.1)
• Documented disease progression
• Patients with progression after anthracycline and/or taxane treatment (palliative or adjuvant)
• Life expectancy of at least 12 weeks
• Performance status 0-2
• Adequate hematology, liver and renal function:
o Hematologic:
o ANC (absolute neutrophil count) ≥ 1.5 x 109/L
o Hemoglobin ≥ 9 g/dL
o Platelets ≥ 100 x 109/L
o Liver Function:
o Albumin ≥ 2.5 g/dL
o Serum bilirubin ≤ 2 mg/dL
o AST and ALT ≤ 3 x ULN without liver metastases
≤ 5 x ULN if documented liver metastases
o Renal Function:
o Serum Creatinine ≤ 1.5 mg/dL OR Calculated Creatinine Clearance ≥ 40 mL/min

Öffentliche Downloads

MBC-6 Folder
Kurzbeschreibung der MBC-6 Studie



Top